KNSA
Kiniksa Pharmaceuticals International plc. - Class A (KNSA)
Healthcare • NASDAQ • $79.45+1.09%
- Symbol
- KNSA
- Exchange
- NASDAQ
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Price
- $79.45
- Daily Change
- +1.09%
- Market Cap
- $6.13B
- Trailing P/E
- 79.38
- Forward P/E
- 48.59
- 52W High
- $82.98
- 52W Low
- $35.20
- Analyst Target
- $98.00
- Dividend Yield
- 0.00%
- Beta
- 0.04
Kiniksa Pharmaceuticals International, plc, a biopharmaceutical company, develops and commercializes medical therapies in the United States, the United Kingdom, and internationally. The company offers ARCALYST, an interleukin-1alpha and 1beta cytokine trap for the treatment of recurrent pericarditis, a chronic autoinflammatory cardiovascular disease and cardiac sarcoidosis. It also develops KPL-387, an investigational and fully human immunoglobulin G2 monoclonal antibody, which is Phase 2/3 clinical trial for the treatment of recurrent pericarditis; and KPL-116, a Fc-modified immunoglobulin G2 monoclonal antibody, which is in pre-clinical stage. The company was formerly known as Kiniksa Pharmaceuticals, Ltd. and changed its name to Kiniksa Pharmaceuticals International, plc in June 2024. K…
Company websiteResearch KNSA on Stk-Ai
Stk-Ai gives you screening across 100+ fundamental metrics, AI-powered analysis, target predictions, backtested signals, and portfolio tracking — all in one place.
Data shown is for informational purposes only and is not investment advice. Prices and metrics may be delayed.